NEW YORK (GenomeWeb News) – Atossa Genetics today announced a distribution deal with Thermo Fisher Scientific's Fisher HealthCare for Atossa's ForeCYTE breast cancer test.
Fisher Healthcare will distribute the ForeCYTE Breast Health device, consisting of Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT, pump and ForeCYTE patient collection kits. ForeCYTE is a risk stratification test for breast cancer.
Financial and other terms of the deal were not disclosed.
Earlier this week, Atossa announced an agreement with preferred provider organization HealthSmart. Last month, the Seattle-based company signed a deal with Millennium Healthcare for distribution of ForeCYTE in the New York metro area and northern New Jersey.